Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer.
Overview
Stanley Druckenmiller isn't afraid to take risks. His boldness has paid off through the years. Druckenmiller's net worth stands at $7.8 billion. His Duquesne Family Office has roughly $3 billion in assets under management.
One notable example of Druckenmiller's risk-taking is his investments in clinical-stage biotech stocks. In the first quarter of 2026, his Duquesne Family Office initiated a new stake in Revolution Medicines (NASDAQ: RVMD) worth $30.7 million at the end of Q1.
Details
Over the last 12 months, Revolution Medicines has surged by more than 400%. Is this high-flying biotech stock still a buy?
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.